Abstract:Due to the limitations of available in vitro systems and animal models, we lack a detailed understanding of the pathogenetic mechanisms and have minimal treatment options for liver fibrosis. To overcome this barrier, we engineered a live cell imaging system that identifies collagen producing cells in a human multi-lineage hepatic organoid. This system was adapted for use as a microwell-based platform (i.e., microHOs) where exposure to PDGF or TGFb1 induced the formation of thick collagen fibers. Transcriptomic analysis revealed that TGFb1 exposure converted mesenchymal cells into myofibroblast-like cells that contribute to the development of liver fibrosis. When pro-fibrotic intracellular signaling pathways were examined using pharmacological probes, the anti-fibrotic effect of receptor-specific tyrosine kinase inhibitors was limited to the fibrosis induced by the corresponding growth factor, which indicates that their anti-fibrotic efficacy would be limited to fibrotic diseases that were solely mediated by that growth factor. Transcriptomic and transcription factor activation analyses were used to identify pathways that were jointly activated by PDGF and TGFb1. GSK3b; or p38 MAPK inhibitors could prevent TGFb1- or PDGF-induced fibrosis in microHOs because they block intracellular signaling pathways that are commonly utilized by the TGFb1 and PDGF receptors. Hence, these studies identified GSK3b and p38 MAPK inhibitors as potential new broad-spectrum therapies for liver fibrosis, and it is likely that other new therapies could subsequently be identified using this microHO system.

What problem does this paper attempt to address?

This paper attempts to address the issues present in liver fibrosis research, particularly the limitations of existing in vitro systems and animal models that lead to an insufficient understanding of the pathological mechanisms of liver fibrosis and limited treatment options. To overcome these obstacles, researchers developed a live-cell imaging system to identify collagen-producing cells in human multi-lineage liver organoids. This system was adapted into a microplate platform (i.e., micro liver organoids, microHOs) and induced the formation of thick collagen fibers by exposure to platelet-derived growth factor (PDGF) or transforming growth factor β1 (TGF-β1). Transcriptomic analysis revealed that TGF-β1 transforms mesenchymal cells into myofibroblast-like cells, contributing to liver fibrosis. Additionally, pharmacological probes were used to study the pro-fibrotic intracellular signaling pathways, and it was found that receptor-specific tyrosine kinase inhibitors were effective only against fibrosis induced by specific growth factors, suggesting that their anti-fibrotic effects might be limited to fibrosis diseases mediated by a single growth factor. Through transcriptomic and transcription factor activation analysis, signaling pathways co-activated by PDGF and TGF-β1 were identified, and it was discovered that GSK3β or p38 MAPK inhibitors could prevent fibrosis induced by TGF-β1 or PDGF in micro liver organoids. Therefore, this study identifies GSK3β and p38 MAPK inhibitors as potential new broad-spectrum treatments for liver fibrosis and suggests that this micro liver organoid system could be used in the future to identify other new therapeutic methods.

Characterization of Pro-Fibrotic Signaling Pathways using Human Hepatic Organoids